Introduction: The Challenge of Cartilage Repair

Cartilage damage is a pervasive clinical problem. It arises from acute injuries such as sports-related trauma or meniscal tears, from chronic overload in obesity, and, most commonly, from degenerative diseases like osteoarthritis (OA). In the United States alone, osteoarthritis affects more than 32.5 million adults, and the number is rising with an aging population. Once damaged, articular cartilage has a notoriously poor intrinsic healing capacity. This is due to its avascular nature, low cellularity, and the limited mitotic activity of chondrocytes, the resident cells. Consequently, even minor defects can progress to joint pain, stiffness, and loss of function.

Over the past two decades, regenerative medicine has turned to growth factors as key regulators of cartilage repair. These naturally occurring proteins orchestrate the cellular events needed for regeneration: they stimulate chondrocyte proliferation, induce extracellular matrix (ECM) synthesis, and guide the differentiation of stem cells into functional cartilage-forming cells. Understanding how growth factors influence cartilage cell biology is therefore essential for developing next-generation therapies. This article reviews what growth factors are, identifies the most important ones for cartilage regeneration, explains their role in chondrocyte differentiation, surveys current therapeutic applications, and highlights emerging research directions.

What Are Growth Factors?

Growth factors are signaling proteins secreted by cells that bind to specific transmembrane receptors on target cells. This binding initiates intracellular signal transduction cascades — most notably the Smad pathway (for TGF-β family members), the MAPK/ERK pathway, and the PI3K/Akt pathway. These cascades ultimately modulate gene expression, controlling processes such as cell division, matrix production, and differentiation.

Growth factors act in a paracrine (local), autocrine (same cell), or endocrine (systemic) fashion. Their effects are highly context-dependent: the same factor can promote proliferation in one cell type and differentiation in another. In the joint environment, growth factors are released by chondrocytes themselves, by synovial cells, and by infiltrating inflammatory cells after injury. Endogenous levels are typically low, and their natural delivery is spatially and temporally regulated. For therapeutic purposes, researchers aim to recapitulate this regulation to drive effective repair without adverse effects such as uncontrolled tissue growth or osteophyte formation.

Key Growth Factors in Cartilage Regeneration

Multiple growth factors have been identified as critical for normal cartilage homeostasis and repair. The most extensively studied belong to the transforming growth factor-β (TGF-β) superfamily, the insulin-like growth factor (IGF) family, and the fibroblast growth factor (FGF) family.

Transforming Growth Factor‑β (TGF‑β) and Bone Morphogenetic Proteins (BMPs)

TGF-β itself (isoforms 1, 2, and 3) is a potent inducer of chondrogenesis. It stimulates mesenchymal stem cells (MSCs) to differentiate into chondrocytes and promotes the synthesis of collagen type II and aggrecan, the major ECM components of hyaline cartilage. However, TGF-β can also induce fibrotic responses and osteophyte formation if not carefully controlled.

Bone morphogenetic proteins (BMPs) are part of the same superfamily. BMP-2, BMP-4, and BMP-7 (also known as osteogenic protein-1, OP-1) are particularly chondrogenic. BMP-7 is approved for use in spinal fusion and has been investigated for cartilage repair. It stimulates matrix production and protects chondrocytes from apoptosis. BMP-2 is also used in bone regeneration and has shown promise in cartilage defect models, though it carries a risk of ectopic bone formation. A growing body of evidence suggests that a combination of TGF-β and BMP signaling may be required for optimal hyaline cartilage formation.

Insulin‑like Growth Factor‑1 (IGF‑1)

IGF-1 is a major anabolic factor for cartilage. It enhances chondrocyte proliferation, survival, and matrix synthesis (especially aggrecan and collagen type II). IGF-1 levels decrease with age and in osteoarthritic joints, which may contribute to the age-related decline in cartilage repair capacity. In preclinical models, intra-articular injections of IGF-1 have improved cartilage healing, but rapid clearance from the joint and the presence of IGF-binding proteins (IGFBPs) impede its efficacy. Strategies to prolong IGF-1 retention, such as binding it to biomaterials, are under investigation.

Fibroblast Growth Factors (FGFs)

FGF-2 (basic FGF) stimulates the proliferation of chondrocytes and MSCs and protects cartilage from degradation by upregulating tissue inhibitor of metalloproteinases (TIMPs). FGF-18 (sprifermin) has advanced furthest in clinical development. In a phase 2 randomized trial in patients with knee osteoarthritis, intra-articular injections of sprifermin resulted in dose‑dependent increases in cartilage thickness as measured by MRI, without serious adverse events. Phase 3 trials are ongoing. FGF-18 appears to stimulate both cartilage matrix production and chondrocyte proliferation while inhibiting hypertrophic differentiation — a key advantage for maintaining a stable articular cartilage phenotype.

Other Notable Growth Factors

Platelet‑derived growth factor (PDGF) promotes MSC proliferation and migration. Connective tissue growth factor (CTGF, now CCN2) acts in concert with TGF-β to enhance chondrogenesis. Growth differentiation factor‑5 (GDF‑5, also known as CDMP‑1) is essential for joint development and has been used in preclinical cartilage repair studies. Finally, transforming growth factor‑β‑induced gene‑H3 (βig‑h3) and epidermal growth factor (EGF) also modulate chondrocyte behavior, but their roles are less well characterized.

The Role of Growth Factors in Cartilage Cell Differentiation

Cartilage cell differentiation — the process by which immature mesenchymal stem cells (MSCs) become committed chondrocytes — is a central event in both development and repair. This process is termed chondrogenesis. It proceeds through a series of well‑defined stages: mesenchymal condensation, proliferation, chondroblast differentiation, and maturation into hypertrophic chondrocytes (the latter being typical of growth plate development but undesirable in articular cartilage). Growth factors govern each step.

Initiation of Chondrogenesis

TGF-β and BMPs are the primary drivers of the early stages. When MSCs are exposed to TGF-β3 or BMP-2 in vitro, they upregulate transcription factors Sox9, L-Sox5, and Sox6. Sox9 is considered the master regulator of the chondrocyte phenotype: it directly activates genes encoding collagen type II, aggrecan, and other cartilage‑specific matrix proteins. BMPs also induce noggin and gremlin, which act as negative feedback regulators to fine‑tune signaling intensity. FGF signaling, particularly through FGF receptor 3 (FGFR3), can either promote or inhibit chondrogenesis depending on the stage and dose.

Maturation and Maintenance

Once cells become chondrocytes, they must be prevented from undergoing terminal hypertrophic differentiation, during which they produce collagen type X and eventually mineralize the matrix — a process that leads to endochondral ossification and is inappropriate in articular cartilage. IGF-1 and TGF-β help maintain the stable phenotype. FGF‑18, as noted, also suppresses hypertrophy. In contrast, prolonged exposure to inflammatory cytokines such as IL-1β or TNF‑α can drive chondrocytes toward a catabolic state, undermining repair. Thus, the balance between anabolic growth factors and catabolic inflammatory signals is critical.

Differentiation in the Injured Joint

After cartilage injury, the local microenvironment contains a mixture of growth factors released from the damaged tissue and from the synovium. MSCs from bone marrow or synovial fluid respond to these signals. However, the natural concentration and duration of exposure are often insufficient to trigger robust chondrogenesis. In full‑thickness defects that penetrate the subchondral bone (e.g., after microfracture), MSCs enter the defect but predominantly form fibrocartilage, not hyaline cartilage, because the growth factor milieu favors fibroblastic differentiation. This explains the clinical need for exogenously delivered growth factors or for cell‑based therapies that combine MSCs with specific chondrogenic cues.

Growth Factors in Cartilage Repair: Therapeutic Applications

Harnessing growth factors for cartilage repair has been pursued through several overlapping strategies: direct intra‑articular injection, controlled release from biomaterial scaffolds, incorporation into cell‑based therapies, and gene therapy to achieve sustained local expression.

Direct Injection

The simplest approach is to inject a growth factor solution into the joint. Early animal studies showed that single or repeated injections of TGF‑β, BMP‑7, or IGF‑1 could enhance cartilage healing. However, translation to humans has been hampered by short half‑lives (minutes to a few hours), rapid clearance via the synovium, and off‑target effects. For instance, TGF‑β injections in rabbit knees stimulated cartilage repair but also caused synovial hyperplasia and osteophyte formation. Sprifermin (FGF‑18) is the only growth factor to have shown significant structural benefit in a randomized controlled trial for knee osteoarthritis, with no severe safety signals reported. It is now in late‑stage clinical development.

Biomaterial Delivery Systems

To overcome the pharmacokinetic limitations, researchers have developed biomaterial carriers that release growth factors in a controlled, sustained, and sometimes spatially defined manner. Common carriers include hydrogels (e.g., hyaluronic acid, alginate, polyethylene glycol), collagen sponges, synthetic polymer scaffolds, and decellularized ECM. These materials can be loaded with one or more growth factors and implanted into the cartilage defect. For example, a collagen scaffold functionalized with BMP‑7 has been tested in animal models and showed improved chondrogenesis. Another promising approach is the use of smart hydrogels that release growth factors in response to matrix metalloproteinase (MMP) activity or pH changes that occur in the damaged joint.

Cell‑Based Therapies Combined with Growth Factors

In autologous chondrocyte implantation (ACI) and its matrix‑assisted variant (MACI), chondrocytes are expanded ex vivo and re‑implanted. The cells can be pretreated with growth factors to enhance their matrix‑forming ability. Additionally, the biomatrix used in MACI can be impregnated with TGF‑β or BMPs. Mesenchymal stem cell therapies represent a more scalable option. MSCs from bone marrow, adipose tissue, or synovium are often expanded in culture with TGF‑β3 or BMP‑2 to prime them for chondrogenesis before implantation. Clinical trials are evaluating the efficacy of MSC‑seeded scaffolds with growth factors for treating focal cartilage defects and early osteoarthritis. A recent meta‑analysis of cell‑based therapies for knee cartilage defects reported superior outcomes when growth factor supplementation was included.

Gene Therapy Approaches

Gene therapy offers the potential for long‑term, local expression of growth factors. Vectors (typically adeno‑associated virus, AAV, or non‑viral plasmids) carrying the gene for TGF‑β, BMP‑2, or IGF‑1 are delivered into the joint or directly into chondrocytes. Preclinical studies in horses and sheep have shown that AAV‑mediated TGF‑β1 gene transfer can promote healing of focal defects and prevent OA progression. Safety concerns (immunogenicity, insertional mutagenesis, and uncontrolled expression) remain, but ongoing advances in vector design and regulation are moving this strategy toward clinical testing. A phase 1 trial of AAV‑IGF‑1 in ankle osteoarthritis is registered (NCT02727777). Gene editing with CRISPR/Cas9 might enable precise activation of endogenous growth factor genes.

Platelet‑Rich Plasma (PRP) as a Growth Factor Cocktail

PRP is a concentrate of autologous blood containing supraphysiological levels of many growth factors, including PDGF, TGF‑β, IGF‑1, VEGF, and FGF. It is widely used in orthopedics for soft tissue and cartilage injuries, although evidence for its efficacy in cartilage repair remains mixed. PRP’s advantage is its simplicity: one‑step processing of the patient’s blood yields a cocktail that reflects the natural wound‑healing environment. The major drawback is the variability among preparations — platelet concentration, leukocyte content, and activation method all affect the final growth factor profile. Standardization protocols are being developed, and some studies suggest that leukocyte‑poor PRP yields better results for cartilage. Two systematic reviews (e.g., Chen et al., 2020) concluded that PRP injections modestly reduce pain and improve function in knee OA, particularly in younger patients with early disease.

Emerging Research and Future Directions

Despite the promise, translating growth factor therapies into routine clinical use has been slow. Key obstacles include precise dosing, spatiotemporal control, avoidance of ectopic tissue formation, and cost. The research community is pursuing several innovative solutions.

Combinatorial and Sequential Delivery

Cartilage development and healing involve a sequence of growth factor signals. Mimicking this sequence — for example, delivering TGF‑β early to induce chondrogenesis, then switching to IGF‑1 and FGF‑18 to stabilize the phenotype — could yield more robust and durable repair. Advanced drug delivery systems now allow for multi‑stage release from a single scaffold. Layer‑by‑layer coatings and core‑shell fibers are being engineered to release different factors at different times.

Exosomes and Paracrine Mediators

An emerging paradigm is that the therapeutic effects of MSCs are largely mediated by their secretome, including exosomes (extracellular vesicles). These vesicles carry growth factors, mRNA, and microRNAs that can modulate recipient cell behavior without the need for whole‑cell engraftment. Exosomes loaded with TGF‑β or BMP‑2 have shown chondroprotective effects in animal models. Using exosomes as a delivery vehicle may reduce the risks of immune rejection and tumorigenicity. Research is ongoing to understand the optimal loading and targeting strategies.

Personalized Growth Factor Profiles

Individual patients likely require different growth factor combinations and doses depending on their age, genetic background, disease severity, and joint biology. Liquid biopsy analyses (synovial fluid proteomics) can profile the growth factors and cytokines present in a patient’s joint. This information might guide a personalized treatment, such as selecting which factor to supplement or antagonize. For instance, joints with high levels of IL‑1β might benefit from concomitant anti‑inflammatory therapy. The OA Biomarker Initiative aims to facilitate such tailored approaches.

Improved Scaffolds and 3D Bioprinting

Three‑dimensional (3D) bioprinting allows precise placement of cells, growth factors, and biomaterials to fabricate cartilage constructs layer by layer. Growth factors can be incorporated into the printing inks (bioinks) at controlled concentrations. Recent studies have demonstrated printing of TGF‑β‑loaded hydrogels that support MSC chondrogenesis and produce cartilage‑like tissue with zonal organization. The ability to spatially pattern growth factors — for example, high BMP concentration in the deep zone and high TGF‑β near the surface — could better mimic native cartilage architecture.

Conclusion

Growth factors are indispensable regulators of cartilage cell differentiation and repair. From initiating chondrogenesis in MSCs to maintaining the stable phenotype of articular chondrocytes, these signals orchestrate every step of the regenerative process. While simple injection strategies have met with limited success due to pharmacokinetic barriers, innovations in biomaterial delivery, cell combination, and gene therapy are bringing growth factor treatments closer to clinical reality. The demonstrated structural benefit of FGF‑18 sprifermin in a large phase 2 trial and the growing sophistication of combinatorial and sequential release systems signal a promising future. Continued research — focused on safety, long‑term efficacy, and patient stratification — will determine how quickly growth factor‑based therapies become part of the standard armamentarium for cartilage damage and osteoarthritis. For clinicians and researchers alike, understanding these molecular regulators is essential for advancing the field of joint preservation and regeneration.

For further reading, see the NCBI review on growth factors in cartilage repair and the Nature Reviews Rheumatology article on sprifermin.